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RSV = respiratory syncytial virus; tPTEF/tE = exhaled time to reach peak expiratory flow as a fraction of total expiratory time; VmaxFRC = maximal flow at
functional residual capacity produced by forced expiration as a result of a rapid chest compression; VPTEF/VE = tidal volume exhaled at peak tidal
expiratory flow as a fraction of total tidal volume.
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In this issue of Critical Care, Totapally and colleagues [1]
evaluate the effect of albuterol on tidal breathing loops of 20
infants with respiratory syncytial virus (RSV) bronchiolitis. They
found that the wheeze score and the pulmonary function tests
were not significantly affected by albuterol. This is the latest of
12 randomised controlled trials in 12 years [2–12], involving
843 infants, that evaluated the effect of bronchodilators on
bronchiolitis. After so many trials, have we resolved whether
bronchodilators have a role in the management of bronchiolitis,
and have pulmonary function measurements been helpful?
Salbutamol, albuterol and ipratropium bromide
Of the 12 most recent randomised controlled trials published
in English, evaluating the effect of salbutamol or albuterol on
bronchiolitis, nine (75%) showed that bronchodilators had no
effect. In three of these studies, some difference had been
observed [3,11,12], yet it resulted in only a small transient
improvement in the acute clinical score and had no effect on
hospital admission rates or duration of stay in hospital. In one
of these three studies [11], ex-premature infants who might
have had some mild underlying chronic lung disease, which
might have resulted in the response to bronchodilators, were
not excluded. Several studies reported an increase in heart
rate [12] or a decrease in oxygen saturation [3] after
salbutamol or albuterol.
The effect of ipratropium bromide (either alone or in
combination with salbutamol or albuterol) on bronchiolitis has
been evaluated in four recent randomised controlled trials
[5,6,9,13] and none has shown any significant effect.
Nebulised adrenaline
In contrast, there have been five published randomised
controlled trials in the last 10 years, involving 225 infants,
evaluating the effect of nebulised adrenaline (epinephrine) on
bronchiolitis [7,14–17]. All five (100%) have shown
significant clinical improvement in infants with bronchiolitis,
with decreases in oxygen requirement, respiratory rate,
wheeze and retractions. Menon [14] showed lower hospital
admission rates, and Bertrand et al. [15] found that the group
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Abstract
Over the past 12 years there have been 12 randomised control trials, involving 843 infants, evaluating
the effect of salbutamol or albuterol on bronchiolitis. Of these, nine (75%) showed that bronchodilators
had no effect. In three studies a small transient improvement in the acute clinical score was seen.
Ipratropium bromide had no significant effect. There have been five recent randomised trials involving
225 infants, evaluating the effect of nebulised adrenaline (epinephrine) on bronchiolitis. All five (100%)
have shown significant clinical improvement, with reductions in oxygen requirement, respiratory rate
and wheeze after nebulised adrenaline. Two showed lower hospital admission rates and earlier
discharge with adrenaline. A significant improvement in pulmonary resistance was observed after
nebulised adrenaline but not after salbutamol or albuterol. Currently there is no compelling evidence
that bronchodilators have a role in the routine management of infants with bronchiolitis. There is better
evidence for the use of nebulised adrenaline.
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given nebulised adrenaline were discharged from hospital
earlier. A significant improvement in pulmonary resistance
was also observed [16]. The incidence of side effects is no
more frequent with nebulised adrenaline than with
salbutamol. The 90-minute heart rate was often significantly
lower in the adrenaline group, and although pallor was noted
more frequently it was transient and of no known clinical
significance [14].
Pathophysiology
These results suggest that mucosal swelling and mucous
plugging make a greater contribution to the increased airway
resistance observed in bronchiolitis than constriction of
bronchial smooth muscle. Barr et al. [18] found a beneficial
effect of inhaled adrenaline in an infant with RSV bronchiolitis
who was also receiving β-adrenergic receptor blockade with
propranolol. This indicates that it was most probably the α-
adrenergic stimulation that was improving airway obstruction
by inducing arteriolar vasoconstriction in the airway mucosa
and thus reducing bronchial mucosal thickness.
Pulmonary function tests
Of the 12 randomised studies evaluating the effect of
bronchodilators on bronchiolitis, only in those by Totapally et
al. [1] and Sly et al. [10] were any pulmonary function
measurements made. Totapally used tidal breathing flow-
volume loops to assess the effect of albuterol on infants with
bronchiolitis, and they found no significant change. Two main
calculations were made: the exhaled time to reach peak
expiratory flow as a fraction of total expiratory time (tPTEF/tE)
and the tidal volume exhaled at peak tidal expiratory flow as a
fraction of total tidal volume (VPTEF/VE).
The time needed to reach peak tidal expiratory flow is highly
influenced by the activity of the laryngeal abductors and
adductors, abdominal and intercostal expiratory muscles,
post-inspiratory activity of the diaphragm and intercostal
muscles, and vagal nerve tone [19,20]. Changes in these
muscle activities could cause significant alterations in tPTEF/tE
independently of changes in the resistance and compliance
of airways and lung. Thus tPTEF/tE is an insensitive measure of
airway function in infants and children in comparison with
VmaxFRC (maximal flow at functional residual capacity
produced by forced expiration as a result of a rapid chest
compression) and other more invasive techniques [19].
Sly et al. [10] performed a randomised trial of salbutamol in
infants with bronchiolitis and measured VmaxFRC and found no
significant change.
Sanchez [16] also conducted pulmonary function tests in a
crossover trial comparing salbutamol with racemic
adrenaline. As in other studies, administering salbutamol
resulted in no change, whereas adrenaline significantly
decreased pulmonary resistance. Sanchez et al. used a more
invasive technique, measuring transpulmonary pressures
(with an oesophageal catheter), flow and volume to
determine pulmonary resistance by a least-mean-square
technique. They excluded breaths in which the leak was
greater than 10%, the correlation coefficient was less than
0.95 or the tidal volume was less than 0.5 ml/kg, to eliminate
the analysis of shallow breaths and artefacts.
Leaks around the mask or around an uncuffed endotracheal
tube can cause major errors in the pulmonary function
measurements and lead to gross overestimation of compliance
and resistance [21]. The inspired and expired volumes need to
be within 10% of each other to allow an accurate analysis.
Totapally et al. did not specify the minimum acceptable leak in
their study. Ideally, absolute lung volume should also be
measured to help in the interpretation of resistance changes;
however, this is invasive and difficult to perform.
Conclusion
Although Totapally and colleagues should be commended for
performing pulmonary function measurements to assess
further the effect of albuterol on infants with bronchiolitis, the
pulmonary function results need to be interpreted with a
degree of caution. However, in view of the general lack of
effect of bronchodilators in bronchiolitis in other studies, I do
not think that any significant effect of albuterol on pulmonary
function was missed in this study. It also highlights the urgent
need for a simple non-invasive test that can measure lung
function in infants more accurately.
In summary, there is no compelling evidence that
bronchodilators have a role in the routine management of
infants with bronchiolitis. There is better evidence for the use
of nebulised adrenaline, which results in a reduction of the
airway mucosal oedema, leading to symptomatic
improvement, improved pulmonary function and shorter
hospital admissions.
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